Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients

Heterogeneity of current clinical practice

S. Trifilio, Amit K. Verma, J. Mehta

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Antimicrobial agents are commonly used after hematopoietic stem cell transplant (HSCT) to prevent bacterial, viral and fungal infections. A pharmacy practice survey was undertaken to evaluate prevailing practices. The 31 centers evaluated transplanted over 3400 patients in 2001. Over half used bacterial prophylaxis; all with fluoroquinolones. A significantly higher proportion (90-100%) used fungal and viral prophylaxis. Most centers used fluconazole for fungal prophylaxis, but the dose used varied from 400 mg (the recommended dose) to 100 mg. Itraconazole and amphotericin preparations were used by some centers for allograft recipients because of their activity against aspergillosis. Most centers used brief viral prophylaxis for autograft recipients aimed at preventing HSV reactivation. Viral prophylaxis for allograft recipients was usually much more prolonged, reflecting concern over cytomegalovirus infections. Overall, there was significant deviation from recommended guidelines in many of the practices. Our survey suggests that substantial variation exists among transplant centers in their approach to antimicrobial prophylaxis after HSCT. This probably stems from the lack of definitive studies and strong recommendations in several areas, availability of newer agents that have not been adequately studied in the HSCT setting, and a desire to improve outcome before definitive studies are available for newer agents, a process that could take several years.

Original languageEnglish (US)
Pages (from-to)735-739
Number of pages5
JournalBone Marrow Transplantation
Volume33
Issue number7
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
Transplants
Allografts
Itraconazole
Aspergillosis
Mycoses
Fluconazole
Fluoroquinolones
Autografts
Cytomegalovirus Infections
Amphotericin B
Virus Diseases
Anti-Infective Agents
Bacterial Infections
Guidelines
Transplant Recipients
Surveys and Questionnaires

Keywords

  • Antimicrobial agents
  • Infections
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients : Heterogeneity of current clinical practice. / Trifilio, S.; Verma, Amit K.; Mehta, J.

In: Bone Marrow Transplantation, Vol. 33, No. 7, 04.2004, p. 735-739.

Research output: Contribution to journalArticle

@article{39a9cd39a864417c82b71f5f09d2efd1,
title = "Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: Heterogeneity of current clinical practice",
abstract = "Antimicrobial agents are commonly used after hematopoietic stem cell transplant (HSCT) to prevent bacterial, viral and fungal infections. A pharmacy practice survey was undertaken to evaluate prevailing practices. The 31 centers evaluated transplanted over 3400 patients in 2001. Over half used bacterial prophylaxis; all with fluoroquinolones. A significantly higher proportion (90-100{\%}) used fungal and viral prophylaxis. Most centers used fluconazole for fungal prophylaxis, but the dose used varied from 400 mg (the recommended dose) to 100 mg. Itraconazole and amphotericin preparations were used by some centers for allograft recipients because of their activity against aspergillosis. Most centers used brief viral prophylaxis for autograft recipients aimed at preventing HSV reactivation. Viral prophylaxis for allograft recipients was usually much more prolonged, reflecting concern over cytomegalovirus infections. Overall, there was significant deviation from recommended guidelines in many of the practices. Our survey suggests that substantial variation exists among transplant centers in their approach to antimicrobial prophylaxis after HSCT. This probably stems from the lack of definitive studies and strong recommendations in several areas, availability of newer agents that have not been adequately studied in the HSCT setting, and a desire to improve outcome before definitive studies are available for newer agents, a process that could take several years.",
keywords = "Antimicrobial agents, Infections, Prophylaxis",
author = "S. Trifilio and Verma, {Amit K.} and J. Mehta",
year = "2004",
month = "4",
doi = "10.1038/sj.bmt.1704423",
language = "English (US)",
volume = "33",
pages = "735--739",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients

T2 - Heterogeneity of current clinical practice

AU - Trifilio, S.

AU - Verma, Amit K.

AU - Mehta, J.

PY - 2004/4

Y1 - 2004/4

N2 - Antimicrobial agents are commonly used after hematopoietic stem cell transplant (HSCT) to prevent bacterial, viral and fungal infections. A pharmacy practice survey was undertaken to evaluate prevailing practices. The 31 centers evaluated transplanted over 3400 patients in 2001. Over half used bacterial prophylaxis; all with fluoroquinolones. A significantly higher proportion (90-100%) used fungal and viral prophylaxis. Most centers used fluconazole for fungal prophylaxis, but the dose used varied from 400 mg (the recommended dose) to 100 mg. Itraconazole and amphotericin preparations were used by some centers for allograft recipients because of their activity against aspergillosis. Most centers used brief viral prophylaxis for autograft recipients aimed at preventing HSV reactivation. Viral prophylaxis for allograft recipients was usually much more prolonged, reflecting concern over cytomegalovirus infections. Overall, there was significant deviation from recommended guidelines in many of the practices. Our survey suggests that substantial variation exists among transplant centers in their approach to antimicrobial prophylaxis after HSCT. This probably stems from the lack of definitive studies and strong recommendations in several areas, availability of newer agents that have not been adequately studied in the HSCT setting, and a desire to improve outcome before definitive studies are available for newer agents, a process that could take several years.

AB - Antimicrobial agents are commonly used after hematopoietic stem cell transplant (HSCT) to prevent bacterial, viral and fungal infections. A pharmacy practice survey was undertaken to evaluate prevailing practices. The 31 centers evaluated transplanted over 3400 patients in 2001. Over half used bacterial prophylaxis; all with fluoroquinolones. A significantly higher proportion (90-100%) used fungal and viral prophylaxis. Most centers used fluconazole for fungal prophylaxis, but the dose used varied from 400 mg (the recommended dose) to 100 mg. Itraconazole and amphotericin preparations were used by some centers for allograft recipients because of their activity against aspergillosis. Most centers used brief viral prophylaxis for autograft recipients aimed at preventing HSV reactivation. Viral prophylaxis for allograft recipients was usually much more prolonged, reflecting concern over cytomegalovirus infections. Overall, there was significant deviation from recommended guidelines in many of the practices. Our survey suggests that substantial variation exists among transplant centers in their approach to antimicrobial prophylaxis after HSCT. This probably stems from the lack of definitive studies and strong recommendations in several areas, availability of newer agents that have not been adequately studied in the HSCT setting, and a desire to improve outcome before definitive studies are available for newer agents, a process that could take several years.

KW - Antimicrobial agents

KW - Infections

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=15544367832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15544367832&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704423

DO - 10.1038/sj.bmt.1704423

M3 - Article

VL - 33

SP - 735

EP - 739

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -